Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | USP2 | O75604 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.96 |
| ▸ | EGFR | P00533 | 1/20 | 0.96 |
| ▸ | LCK | P06239 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
| ▸ | KDM6B | O15054 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL29519451 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL22095717 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL29373537 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL704089 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL30678311 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL116907 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL22655 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL20582239 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL11000382 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL29975814 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303499-B2 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| CN-113226286-B | Water-based pharmaceutical formulations of 1, 2-dihydropyridine compounds | 卫材R&D管理有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-116036064-A | Levodopa and carbidopa enteric gel and methods of use | 艾伯维公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230129413-A1 | Levodopa and Carbidopa Intestinal Gel and Methods of Use | ABBVIE INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220023275-A1 | Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3893844-A1 | AQUEOUS BASED PHARMACEUTICAL FORMULATIONS OF 1,2-DIHYDROPYRIDINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2021-10-20 | — | — | EP | disclosed |
| CN-113226286-A | Water-based pharmaceutical formulations of 1, 2-dihydropyridine compounds | 卫材R&D管理有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210059968-A1 | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210046029-A1 | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE | ABBVIE INC (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2020124090-A1 | AQUEOUS BASED PHARMACEUTICAL FORMULATIONS OF 1,2-DIHYDROPYRIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-18 | — | — | WO | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| CN-1738618-A | Pharmaceutical compositions and their uses | EISAI CO LTD (JP) | 2006-02-22 | — | — | CN | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1465626-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | Eisai Co., Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | DRD3 279/4885SLC7A5 596/4885KDM4E 879/4885 |
| US-20220023275-A1 | Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine Compounds | GRIK5, GRIK1, GRIK2 | DRD3 596/4885SLC7A5 262/4885KDM4E 2546/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | DRD3 302/4885SLC7A5 759/4885KDM4E 798/4885 |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | DRD3 607/4885SLC7A5 582/4885KDM4E 1727/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | DRD3 1425/4885SLC7A5 4801/4885KDM4E 2880/4885 |
| US-12303499-B2 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds | GRIK5, GRIK1, GRIK2 | DRD3 596/4885SLC7A5 262/4885KDM4E 2546/4885 |
| US-20210059968-A1 | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE | PARK7, COMT, SNCA | DRD3 245/4885SLC7A5 1108/4885KDM4E 4317/4885 |
| US-20230129413-A1 | Levodopa and Carbidopa Intestinal Gel and Methods of Use | PARK7, COMT, SNCA | DRD3 245/4885SLC7A5 1108/4885KDM4E 4317/4885 |
| US-20210046029-A1 | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE | PARK7, SNCA, COMT | DRD3 241/4885SLC7A5 1280/4885KDM4E 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.